BRI Biopharmaceutical Research (a Frontage Laboratories Company since 2019) offers bioanalysis of small molecules, mAb, proteins, siRNA and human gut microbiome biomarker assays in support of preclinical and clinical pharmacokinetics, drug metabolism and CMC studies. Preclinical studies include in vitro protein binding study and in vivo rodent oral bioavailability and ADME studies including the use of radiolabels. In vitro human gut microbiome studies include an array of LC/MS/MS and ELISA assays of biomarkers for correlation of drug metabolism in relation to gut microbiome functional activity and beta diversity.